PD-1/PD-L1

阻害剤の選択性比較

カタログ番号 製品カタログ 溶解度(25°C)
DMSO アルコール
S8158 PD-1/PD-L1 Inhibitor 3 100 mg/mL -1 mg/mL -1 mg/mL
S7912 BMS202 (PD-1/PD-L1 inhibitor 2) <1 mg/mL 83 mg/mL 83 mg/mL
S8549 AUNP-12 100 mg/mL -1 mg/mL -1 mg/mL
S8859 BMS-1166 <1 mg/mL 100 mg/mL '13 mg/mL
S7911 BMS-1 (PD-1/PD-L1 inhibitor 1) 95 mg/mL 95 mg/mL '''95 mg/mL
S8275 Tomivosertib (eFT-508) <1 mg/mL 13 mg/mL ''<1 mg/mL

PD-1/PD-L1製品

製品コード 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
A2002

Nivolumab (anti-PD-1)

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

A2004

Atezolizumab (anti-PD-L1)

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

A2005

Pembrolizumab (anti-PD-1)

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

S8158

PD-1/PD-L1 Inhibitor 3

PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM

S7912

BMS202 (PD-1/PD-L1 inhibitor 2)

BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.

S8549

AUNP-12

AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.

S8859

BMS-1166

BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.

S7911

BMS-1 (PD-1/PD-L1 inhibitor 1)

PD-1/PD-L1 inhibitor 1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.

S8275

Tomivosertib (eFT-508)

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

製品コード 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
A2002

Nivolumab (anti-PD-1)

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

A2004

Atezolizumab (anti-PD-L1)

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

A2005

Pembrolizumab (anti-PD-1)

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

S8158

PD-1/PD-L1 Inhibitor 3

PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM

S7912

BMS202 (PD-1/PD-L1 inhibitor 2)

BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.

S8549

AUNP-12

AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.

S8859

BMS-1166

BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.

S7911

BMS-1 (PD-1/PD-L1 inhibitor 1)

PD-1/PD-L1 inhibitor 1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.

S8275

Tomivosertib (eFT-508)

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

製品コード 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
A2013

Durvalumab (anti-PD-L1)

Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

A2016

Camrelizumab (anti-PD-1)

Camrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.

A2017

Spartalizumab (anti-PD-1)

Spartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.

Tags: PD-1/PD-L1 inhibition | PD-1/PD-L1 cancer | PD-1/PD-L1 signaling pathway | PD-1/PD-L1 assay | PD-1/PD-L1 inhibitor cancer | PD-1/PD-L1 inhibitor review